Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Change in Accured Expenses (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Change in Accured Expenses for 6 consecutive years, with $424899.0 as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 18.08% to $424899.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, up 233.57% year-over-year, with the annual reading at $1.4 million for FY2025, 233.57% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $424899.0 at Inhibikase Therapeutics, down from $718197.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $1.0 million in Q3 2021, with the low at -$1.3 million in Q3 2022.
  • Average Change in Accured Expenses over 5 years is $172417.4, with a median of $246503.0 recorded in 2021.
  • The sharpest move saw Change in Accured Expenses surged 15605.69% in 2022, then plummeted 273.47% in 2024.
  • Over 5 years, Change in Accured Expenses stood at $810751.0 in 2021, then plummeted by 83.67% to $132394.0 in 2022, then skyrocketed by 203.44% to $401740.0 in 2023, then increased by 29.1% to $518656.0 in 2024, then dropped by 18.08% to $424899.0 in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $424899.0, $718197.0, and -$575063.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.